The role of profilin-1 in endothelial cell injury induced by advanced glycation end products (AGEs)
Open Access
- 4 October 2013
- journal article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 141
Abstract
Background: Accumulation of advanced glycation end products (AGEs) in the vasculature triggers a series of morphological and functional changes contributing to endothelial hyperpermeability. The reorganisation and redistribution of the cytoskeleton regulated by profilin-1 mediates endothelial cell contraction, which results in vascular hyperpermeability. This study aimed to investigate the pivotal role of profilin-1 in the process of endothelial cell damage induced by AGEs. Methods: Human umbilical vein endothelial cells (HUVECs) were incubated with AGEs. The mRNA and protein expression of profilin-1 was determined using real-time PCR and western blotting analyses. The levels of intercellular adhesion molecule-1 (ICAM-1), nitric oxide (NO) and reactive oxygen species (ROS), as well as the activities of nuclear factor-κB (NF-κB) and protein kinase C (PKC), were detected using the appropriate kits. The levels of asymmetric dimethylarginine (ADMA) were determined using HPLC. The distribution of the cytoskeleton was visualised using immunofluorescent staining. Results: Compared with the control, incubation of endothelial cells with AGEs (200 μg/ml) for 4 or 24 h significantly up-regulated the mRNA and protein expression of profilin-1, markedly increased the levels of ICAM-1 and ADMA and decreased the production of NO (PP<0.01), which was significantly attenuated by pretreatment with DPI (an antioxidant), GF 109203X (PKC inhibitor) or BAY-117082 (NF-κB inhibitor). DPI (10 μmol/L) markedly decreased the elevated levels of ROS induced by AGEs (200 μg/ml, 24 h); however, GF 109203X (10 μmol/L) and BAY-117082 (5 μmol/L) exhibited no significant effect on the formation of ROS by AGEs. Immunofluorescent staining indicated that AGEs markedly increased the expression of profilin-1 in the cytoplasm and the formation of actin stress fibres, resulting in the rearrangement and redistribution of the cytoskeleton. This effect was significantly ameliorated by DPI, GF 109203X, BAY-117082 or siRNA treatment of profilin-1. Incubation with DPI and GF 109203X markedly inhibited the activation of PKC triggered by AGEs, and DPI and BAY-117082 significantly decreased the activity of NF-κB mediated by AGEs. Disruption of profilin-1 gene expression attenuated the extent of endothelial abnormalities by reducing ICAM-1 and ADMA levels and elevating NO levels (P<0.05, P0.05). Conclusions: These findings suggested that profilin-1 might act as an ultimate and common cellular effector in the process of metabolic memory (endothelial abnormalities) mediated by AGEs via the ROS/PKC or ROS/NF-қB signalling pathways.Keywords
This publication has 39 references indexed in Scilit:
- The emerging challenge in diabetes: The “metabolic memory”Vascular Pharmacology, 2012
- Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cellsCardiovascular Diabetology, 2012
- RhoA/ROCK-dependent moesin phosphorylation regulates AGE-induced endothelial cellular responseCardiovascular Diabetology, 2012
- Profilin-1 Is Expressed in Human Atherosclerotic Plaques and Induces Atherogenic Effects on Vascular Smooth Muscle CellsPLOS ONE, 2010
- Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathwayFEBS Letters, 2009
- Silencing profilin-1 inhibits endothelial cell proliferation, migration and cord morphogenesisJournal of Cell Science, 2006
- Advanced glycation and endothelial functions: A link towards vascular complications in diabetesLife Sciences, 2004
- Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetesCardiovascular Research, 2004
- Profilin acts downstream of LDL to mediate diabetic endothelial cell dysfunctionThe FASEB Journal, 2004
- Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazideDiabetes, Obesity and Metabolism, 2004